CANADA LIFE ASSURANCE Co Buys 126,425 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

CANADA LIFE ASSURANCE Co raised its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 22.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 697,977 shares of the company's stock after acquiring an additional 126,425 shares during the quarter. CANADA LIFE ASSURANCE Co owned approximately 0.06% of Teva Pharmaceutical Industries worth $15,371,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in TEVA. FMR LLC boosted its holdings in Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares during the period. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after buying an additional 4,418,961 shares during the last quarter. Lingotto Investment Management LLP boosted its holdings in shares of Teva Pharmaceutical Industries by 2.6% in the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock valued at $599,320,000 after buying an additional 688,862 shares during the period. Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Teva Pharmaceutical Industries by 2.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock worth $573,822,000 after purchasing an additional 569,412 shares during the period. Finally, Geode Capital Management LLC boosted its position in Teva Pharmaceutical Industries by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company's stock valued at $203,642,000 after purchasing an additional 489,041 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TEVA has been the subject of several recent research reports. Bank of America lowered their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday. UBS Group decreased their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Finally, Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Trading Up 2.9 %

NYSE TEVA traded up $0.42 on Thursday, hitting $14.71. 8,358,482 shares of the company were exchanged, compared to its average volume of 9,938,242. Teva Pharmaceutical Industries Limited has a twelve month low of $12.47 and a twelve month high of $22.80. The company's 50 day moving average price is $15.30 and its 200-day moving average price is $17.60. The firm has a market capitalization of $16.68 billion, a P/E ratio of -10.14, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.